Nijhof et al. [8] reported that in bone marrow samples, Daratumumab induced both CDC and ADCC in vitro effectively, and there is a significant association between Daratumumab-induced CDC/ADCC and the expression level of CD38 in MM patients. The gene discussed is CD38; the disease is Miyoshi myopathy.